(Q38673109)

5 September 2017

title

Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer (English)

1 reference

5 September 2017

8

Cesare Gridelli

1 reference

5 September 2017

Emanuela Rossi

1

1 reference

5 September 2017

Assunta Sgambato

2

1 reference

5 September 2017

Giovanni De Chiara

3

1 reference

5 September 2017

Francesca Casaluce

4

1 reference

5 September 2017

Tania Losanno

5

1 reference

5 September 2017

Paola Claudia Sacco

6

1 reference

5 September 2017

Giuseppe Santabarbara

7

1 reference

5 September 2017

language of work or name

English

0 references

publication date

17 December 2015

1 reference

Expert Review of Clinical Pharmacology

5 September 2017

published in

1 reference

5 September 2017

volume

9

1 reference

5 September 2017

issue

3

1 reference

5 September 2017

page(s)

419-428

1 reference

A decade of advances in treatment for advanced non-small cell lung cancer

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Nivolumab in NSCLC: latest evidence and clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Autoimmunity and treatment outcome in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Drug-induced graves disease from CTLA-4 receptor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

Hyponatremia associated with Ipilimumab-induced hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1133289

10.1586/17512433.2016.1133289

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference